Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cholesterol drug MK-0616 takes on old favorites in Head-to-Head trial

NCT ID NCT06450366

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called MK-0616 (enlicitide) to see if it lowers 'bad' LDL cholesterol better than current pills (ezetimibe, bempedoic acid, or both). About 300 adults with high cholesterol and heart disease risk took part. The main goal was to check cholesterol reduction after 8 weeks and ensure the drug is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

  • Assuta Beersheba MC ( Site 0704)

    Beersheba, 8489507, Israel

  • Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 0901)

    London, England, EC1M 6BQ, United Kingdom

  • CIPREC-CIPREC Sede Arenales ( Site 1000)

    Buenos Aires, Buenos Aires F.D., C1061AAS, Argentina

  • Cambridge Cardiac Care Centre ( Site 1603)

    Cambridge, Ontario, N1R 6V6, Canada

  • Chang Gung Medical Foundation-Linkou Branch ( Site 0404)

    Taoyuan, 33305, Taiwan

  • Clinical Trials Research ( Site 1509)

    Lincoln, California, 95648, United States

  • Diex Recherche Trois-Rivieres ( Site 1602)

    Trois-Rivières, Quebec, G9A 4P3, Canada

  • EAP Sardenya ( Site 0800)

    Barcelona, 08025, Spain

  • Fundacion Estudios Clinicos ( Site 1001)

    Rosario, Santa Fe Province, S2000DEJ, Argentina

  • Healthcare Research Network - Chicago ( Site 1507)

    Flossmoor, Illinois, 60422, United States

  • Hospices Civils de Lyon - Hopital Louis Pradel ( Site 0501)

    Bron, Rhone, 69677, France

  • Hospital San Rafael de Coruna ( Site 0805)

    A Coruña, La Coruna, 15006, Spain

  • Hospital Universitari Vall d'Hebron ( Site 0803)

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 0801)

    Málaga, Andalusia, 29010, Spain

  • Hospital de Figueres ( Site 0804)

    Figueres, Gerona, 17600, Spain

  • Hôpital Arnaud de Villeneuve - CHU Montpellier ( Site 0505)

    Montpellier, Herault, 34090, France

  • Hôpital Bichat - Claude-Bernard ( Site 0504)

    Paris, 75018, France

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-CIC Endocrinology-Diabetology-Nutrition ( Sit

    Nantes, Loire-Atlantique, 44093, France

  • Institut de Cardiologie de Montreal ( Site 1604)

    Montreal, Quebec, H1T 1C8, Canada

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1002)

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • L-MARC Research Center ( Site 1501)

    Louisville, Kentucky, 40213, United States

  • Meir Medical Center. ( Site 0703)

    Kfar Saba, 4428164, Israel

  • National Cheng Kung University Hospital-Internal Medicine ( Site 0403)

    Tainan, 704, Taiwan

  • National Institute for Health Research UCLH Clinical Research Facility ( Site 0908)

    London, London, City of, NW1 2PG, United Kingdom

  • National Taiwan University Hospital ( Site 0400)

    Taipei, 10002, Taiwan

  • North York Diagnostic and Cardiac Centre ( Site 1605)

    North York, Ontario, M6B 3H7, Canada

  • Piedmont Research Partners ( Site 1506)

    Fort Mill, South Carolina, 29707, United States

  • Rainier Clinical Research Center ( Site 1502)

    Renton, Washington, 98057, United States

  • Rambam Health Care Campus ( Site 0700)

    Haifa, 3109601, Israel

  • Royal Free Hospital ( Site 0900)

    London, England, NW3 2QG, United Kingdom

  • Taipei Veterans General Hospital-Department of Medicine ( Site 0402)

    Taipei, 11217, Taiwan

  • The Medical Arts Health Research Group ( Site 1606)

    Vancouver, British Columbia, V7M 2H4, Canada

  • Velocity Clinical Research Rockville ( Site 1503)

    Rockville, Maryland, 20854, United States

  • Velocity Clinical Research, Gulfport ( Site 1505)

    Gulfport, Mississippi, 39503, United States

  • Yitzhak Shamir Medical Center. ( Site 0702)

    Beer Yaakov, 70300, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.